万东医疗2025年年度报告深度解读：战略转型、业绩波动及未来展望

一、关键要点与行业环境

北京万东医疗科技股份有限公司2025年年度报告显示，全球医学影像设备产业正处于技术创新与市场重塑的历史交汇点。人工智能、多模态融合等前沿技术推动行业向精准化、智能化、普惠化发展，传统巨头与新兴力量同台竞技，中国企业在中低端市场实现快速进口替代，并向高端市场突破，国际化步伐明显加快。

• 全球医学影像设备市场2022年规模达525亿美元，预计到2030年增长至627亿美元，亚太市场增速最快（超9.2%），中国企业已成为产业变革的关键变量。
• 技术演进聚焦智能化（AI）、绿色化（无液氦MRI）、便携化，AI医学影像市场年复合增长率超30%，无液氦MRI技术彻底解决冷却资源瓶颈。
• 产业链核心部件仍由国际巨头主导，但中国企业正加强供应链自主可控。
• 商业模式转型，“设备即服务”订阅模式日益流行，诊疗一体化生态成为新趋势。
• 政策层面，《“十四五”医疗装备产业发展规划》《医疗装备产业高质量发展行动计划》等持续利好，国产品牌崛起，技术融合加速行业智能化转型。

二、公司业务与战略布局

2025年是万东医疗承前启后、谋篇布局“十五五”发展的关键之年。公司应对大型医疗设备集采、DRG医保支付改革等挑战，坚持“用户思维、创新突破、结果导向、开放高效”核心价值观，以战略定力和体系能力推动高质量发展。

• 研发投入：同比增长43%，重点布局下一代核心技术预研、产品迭代升级、AI平台开发。
• 市场与渠道：加速全球化战略，国内中高端市场渗透率提升，海外本地化服务网络显著扩展。
• 产品矩阵：
  • 磁共振（MRI）：双子星AI 3.0T MRI上市，填补国内技术空白；第三代无液氦超导MRI全球首发，性能大幅提升，解决液氦资源瓶颈。
  • CT：TurboTom 5 PRO与1S系列覆盖基层到综合医院，AI赋能全流程智慧化，补齐高端产品线。
  • DSA：稀土IGZO探测器降辐射75%，技术获国家高端医疗装备推广应用项目认定。
  • DR：全球首创全脊柱/全下肢一次成像，辐射剂量降低50%，巩固国内市场占有率第一地位。
  • 多元化产品：负重位CBCT、动物专用液金CT、AI核磁等，拓展新市场蓝海。
• 数字医疗平台：
  • 妙笔AI报告生成系统、妙笔AI质控管理系统实现报告规范化、质控全流程管理。
  • 首个DR智能体，多模态诊断大模型实现临床思维链推理，提升诊断能力。
• 全球市场：产品已进入110多个国家，2025年新拓展泰国、印度、墨西哥等20余空白市场，全球客户新增60余家，海外业务实现从出口向技术输出、资本合作、本地化运营升级。
• 知识产权与行业标准：全年新获授权专利45项、软件著作权11项，累计授权知识产权270项，参与国际/国家/行业标准制定，提升行业话语权。
• 产学研合作：与清华大学、中科院电工所等战略合作，牵头国家新材料生产应用示范平台、“十四五”重点研发计划课题。

三、财务表现与股东敏感信息

2025年度业绩表现：

• 营业收入13.47亿元，同比下降11.64%。
• 归属于上市公司股东的净利润-2.28亿元，同比下降244.81%。
• 经营活动现金流量净额-2.52亿元，同比下降215.44%。
• 净资产收益率由3.33%降至-4.94%。
• 基本每股收益由0.224元降至-0.324元。
• 2025年未分红，未转增股本，未送红股。
• 本年度以现金方式回购股份1,802,700股，回购金额2,999.28万元。

股东结构：

• 美的集团为最大股东（45.46%），江苏鱼跃科技、华宝中证医疗ETF等持股。
• 公司与控股股东、实际控制人之间的产权及控制关系稳定。

四、重大事项与未来展望（对股价影响）

• 战略性调整与业绩波动：公司主动进行战略调整与深度转型，短期业绩波动反映结构性压力与前瞻性布局。资源优先配置于长期技术护城河、市场基础、未来增长极的培育，短期利润受压但为高质量增长奠定基础。
• 海外市场突破：外销收入同比增长超50%，已成为增长新引擎。
• 公立医院市场：中标数量翻番，市场份额增长10.23个百分点，但收入确认滞后。
• 私立医院业务下滑：DRG/DIP医保支付改革影响，私立医院需求下滑55%。
• 研发投入与集采参与：高强度研发投入攻克无液氦磁共振等核心技术，积极参与集采优化产品结构，短期挤压毛利率与利润空间。
• 经营性现金流：因集采备货、公立医院信用政策调整、高端人才薪酬增加、海外市场拓展等影响现金流。
• 长期展望：公司已奠定坚实基础，未来海外市场持续拓展、国内中标项目逐步交付、高端产品放量、运营效率提升，将转化为强劲成长动力。
• 无退市风险警示或终止上市情形。

五、投资者关注事项

• 2025年度亏损显著，短期业绩承压，但公司战略转型与海外高增长、研发突破、市场结构优化为长期价值奠定坚实基础。
• 海外业务持续拓展、中标项目逐步转化、高端产品放量等利好因素，有望驱动未来业绩回升。
• 股东需关注公司战略转型与高研发投入对短期利润的影响，以及集采、医保支付政策变化对业务结构和现金流的冲击。
• 公司未分红但进行股份回购，显示对公司长期价值的信心。
• 行业政策持续利好、国产替代加速、技术创新驱动，万东医疗有望在未来高质量发展阶段实现价值重估。

免责声明

本文章内容仅供参考，不构成任何投资建议。投资者应结合自身情况及风险承受能力，审慎决策。公司未来业绩受政策、市场、技术、行业环境等多方面影响，股价可能随业绩波动而变化。请投资者关注公司后续公告及相关信息披露。

Wandong Medical 2025 Annual Report Deep Dive: Strategic Shift, Performance Volatility, and Outlook

1. Key Points and Industry Environment

Beijing Wandong Medical Technology Co., Ltd.’s 2025 annual report highlights that the global medical imaging equipment industry is at a crossroads of technological innovation and market reshaping. Advances in AI and multi-modal fusion are driving the sector toward precision, intelligence, and accessibility. Chinese companies are rapidly replacing imports in the mid-to-low end market and breaking into the high-end, with internationalization speeding up.

• Global medical imaging equipment market reached \$52.5 billion in 2022, projected to grow to \$62.7 billion by 2030, fastest growth in Asia-Pacific (>9.2%), Chinese companies are key disruptors.
• Tech trends: AI integration, green (liquid helium-free MRI), portability, AI imaging market CAGR >30%, liquid helium-free MRI solves key cooling bottleneck.
• Upstream components still dominated by international giants, but Chinese firms are building supply chain autonomy.
• Business models shift: “equipment as a service” subscription gains traction, integrated diagnostic and treatment ecosystem is emerging.
• Policy tailwinds: National plans (14th Five-Year, High-Quality Medical Equipment Industry Action Plan) support domestic innovation, local brands rise, tech fusion accelerates sector’s smart transformation.

2. Company Business & Strategic Layout

2025 marks a critical year for Wandong Medical’s transition and “15th Five-Year Plan” layout. The company responded to centralized procurement and DRG reimbursement reforms by sticking to its core values (user-centricity, innovation, results-driven, openness & efficiency) and strategic discipline, driving high-quality growth.

• R&D: Up 43% YoY, focused on next-gen core tech, product upgrades, deep AI platform development.
• Market & Channels: Accelerated global strategy, deeper penetration in domestic mid-high end, overseas local service network expanded.
• Product Matrix:
  • MRI: Gemini AI 3.0T MRI launched, fills domestic tech gap; 3rd-gen liquid helium-free MRI global debut, performance leap, solves supply bottleneck.
  • CT: TurboTom 5 PRO & 1S series cover clinics to top hospitals, AI powers workflow, high-end line completed.
  • DSA: Rare earth IGZO detector reduces radiation by 75%, recognized by national high-end medical equipment program.
  • DR: World’s first full spine/lower limb single-exposure imaging, radiation down 50%, maintains #1 domestic market share.
  • Diverse products: weight-bearing CBCT, animal liquid metal CT, AI MRI, open new markets.
• Digital Healthcare Platform:
  • Miaobi AI report generation, quality control systems achieve standardized, efficient reporting & full-process QC.
  • First DR AI agent: multi-modal diagnostic model, simulates clinical reasoning, improves accuracy.
• Global Market: Products in 110+ countries, 2025 expansion into 20+ new markets (Thailand, India, Mexico, etc.), 60+ new global clients, overseas business shifts from export to tech transfer, capital cooperation, local ops.
• IP & Standards: 45 new patents, 11 software copyrights, total IP 270; involved in drafting international/national/industry standards.
• Academia-industry: Strategic partnerships with Tsinghua, CAS Institute of Electrical Engineering, led national demo platform, “14th Five-Year” major R&D projects.

3. Financial Performance & Shareholder-sensitive Info

2025 Financials:

• Revenue: RMB 1.347 billion, down 11.64% YoY.
• Net profit: -RMB 228 million, down 244.81% YoY.
• Operating cash flow: -RMB 252 million, down 215.44% YoY.
• ROE: -4.94% (down from 3.33%).
• EPS: -0.324 (down from 0.224).
• No dividends, no bonus shares, no capital increase for 2025.
• Share buyback: 1,802,700 shares, RMB 29.99 million.

Shareholder Structure:

• Midea Group is the largest shareholder (45.46%), followed by Yuyue Technology, Huabao CSI Medical ETF, etc.
• Property/control relations with key shareholders and actual controller remain stable.

4. Major Events & Outlook (Potential Share Price Impact)

• Strategic Transition & Performance Volatility: Company proactively adjusted and transformed, short-term profit hit reflects structural pressures and forward-looking investment. Resources prioritized for long-term tech moat, market foundation, future growth drivers. Short-term profit squeeze, but strong foundation for high-quality growth.
• Overseas Market Breakthrough: External sales up >50%, now a major growth engine.
• Public Hospital Market: Winning bids doubled, market share up 10.23 points, but revenue recognition lags due to procurement, installation, payment cycles.
• Private Hospital Business Down: DRG/DIP payment reforms hit demand, revenue down 55%.
• R&D/Procurement: High R&D spend on core tech (liquid helium-free MRI), aggressive procurement participation, short-term margin/profit squeeze.
• Operating Cash Flow: Hit by procurement stocking, credit policy changes, high-end talent costs, overseas expansion.
• Long-term Outlook: Solid foundation laid, future revenue growth expected as overseas, domestic bid projects, high-end products ramp up, operational efficiency improves.
• No delisting risk warning or termination of listing issues.

5. Investor Takeaways

• 2025 loss is significant, short-term pressure, but strategic transition, overseas growth, tech breakthroughs, and optimized market structure lay groundwork for future value.
• Continued overseas expansion, bid project conversion, high-end product ramp-up expected to drive future recovery.
• Shareholders should monitor strategic transformation, high R&D impact on short-term profits, and procurement/payment policy changes affecting business structure/cash flow.
• No dividend, but share buyback signals management confidence in long-term value.
• Policy tailwinds, domestic substitution, tech innovation all favor Wandong’s high-quality future growth and potential value re-rating.

Disclaimer

The content of this article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own circumstances and risk tolerance. Future performance is subject to policy, market, technology, and industry changes, and share prices may fluctuate with results. Please follow subsequent company announcements and disclosures.

View 万东医疗 Historical chart here